Please assess the completion status of the following clinical trial:

Trial Title: Combinatory ImmunoTherapy-1 (Com-IT-1) Irradiation and PD-1 Blockade in Locally Advanced / Advanced NSCLC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~5.1.1 Subject Inclusion Criteria~* Age \>18 years~* Advanced NSCLC~* Adequate newly obtained core or excisional biopsy of a recurrent tumor lesion~* Adequate is defined as a biopsy with at least 5 sections tumour tissue available.~* Measurable disease according to RECIST criteria~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~* Life expectancy \> 3 months~* A tumour lesion suitable for radiotherapy treatment~* Adequate organ function based on clinical examination and lab values (Hb \>9.0, Leucocytes \> 2.0, Trc \> 100, AST/ALT \<3 ULN)~* Women must not be pregnant or breastfeeding~* WOCBP should use an adequate highly effective method to avoid pregnancy for 23 weeks~* For the purpose of this document, a woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy.~  * Highly effective contraception methods includes methods that can achieve a failure rate of less than 1% per year when used consistently and correctly. Such methods include:~ * combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal)~ * progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable)~ * intrauterine device (IUD)~ * intrauterine hormone-releasing system ( IUS)~ * bilateral tubal occlusion~ * vasectomised partner~* sexual abstinence ___________________________________~* Males who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for a period of 90 days (duration of sperm turnover) plus the time required for the investigational drug to undergo five half-lives~* Previously untreated or treated NSCLC pts, where treatment with PD1-inhibitor in indicated according to national guidelines.~Exclusion Criteria:~5.1.2 Subject Exclusion Criteria~* Disease suitable for curative salvage surgery~* Treatment with any investigational medicinal product (IMP) that may interfere with the study treatment, within 2 weeks prior to first administration of study drug.~* Significant cardiac, pulmonary or other medical illness that would limit activity or survival~* Pregnancy or lactation.~* Patients with EGFR-mutation or ALK-translocation not treated with tyrosine kinase inhibitor previously~* Known hypersensitivity to any of the components of the investigational product~* Patients who test positive for hepatitis B, C or HIV.~* Known active brain metastases. Patients with stable / treated brain metastases can be included.~* Diagnosis of immunodeficiency or medical condition requiring high doses (\>30 mg prednisolone daily) of systemic steroids or other forms of immunosuppressive therapy~* Any reason why, in the opinion of the investigator, the patient should not participate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PDL1-inhibitor and radiotherapy (Type: EXPERIMENTAL): PDL1-inhibitor (Atezolizumab) and Radiotherapy (6 Gy x 3)

Based on this trial design, predict the completion outcome and termination type (if applicable).